Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Suicide | 22 | 2024 | 1601 | 3.140 |
Why?
|
Deductibles and Coinsurance | 13 | 2022 | 316 | 2.800 |
Why?
|
United States Food and Drug Administration | 9 | 2024 | 1661 | 1.910 |
Why?
|
Drug Utilization | 10 | 2017 | 1188 | 1.780 |
Why?
|
Drug Prescriptions | 12 | 2016 | 1669 | 1.720 |
Why?
|
Antidepressive Agents | 10 | 2024 | 2893 | 1.600 |
Why?
|
National Health Programs | 11 | 2022 | 440 | 1.580 |
Why?
|
Taiwan | 13 | 2024 | 521 | 1.420 |
Why?
|
Drug Labeling | 3 | 2024 | 248 | 1.300 |
Why?
|
Neonatal Screening | 4 | 2023 | 597 | 1.240 |
Why?
|
Genetic Testing | 10 | 2024 | 3536 | 1.190 |
Why?
|
Mass Media | 3 | 2014 | 303 | 1.150 |
Why?
|
Product Surveillance, Postmarketing | 4 | 2014 | 452 | 1.080 |
Why?
|
Bipolar Disorder | 9 | 2022 | 5091 | 1.080 |
Why?
|
Health Expenditures | 11 | 2023 | 2363 | 1.070 |
Why?
|
Suicide, Attempted | 6 | 2024 | 1402 | 1.060 |
Why?
|
Rare Diseases | 4 | 2020 | 623 | 1.040 |
Why?
|
Insurance, Health | 12 | 2022 | 2494 | 1.000 |
Why?
|
Australia | 20 | 2024 | 1246 | 0.960 |
Why?
|
Drug Costs | 9 | 2023 | 1183 | 0.950 |
Why?
|
Heart Diseases | 3 | 2024 | 2795 | 0.890 |
Why?
|
Health Policy | 7 | 2018 | 2680 | 0.880 |
Why?
|
Hippocratic Oath | 1 | 2022 | 16 | 0.840 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2017 | 385 | 0.830 |
Why?
|
Medicine | 3 | 2022 | 942 | 0.810 |
Why?
|
Thiazolidinediones | 2 | 2015 | 460 | 0.790 |
Why?
|
Heart Function Tests | 2 | 2013 | 318 | 0.790 |
Why?
|
Adrenergic beta-2 Receptor Agonists | 1 | 2022 | 110 | 0.780 |
Why?
|
Medicaid | 9 | 2017 | 2814 | 0.780 |
Why?
|
Reimbursement Mechanisms | 6 | 2020 | 667 | 0.750 |
Why?
|
Privacy | 1 | 2023 | 233 | 0.720 |
Why?
|
Genomics | 7 | 2024 | 5828 | 0.700 |
Why?
|
Patient Acceptance of Health Care | 7 | 2022 | 3197 | 0.700 |
Why?
|
Cost of Illness | 2 | 2019 | 1937 | 0.650 |
Why?
|
Antipsychotic Agents | 5 | 2022 | 3063 | 0.640 |
Why?
|
Genetic Privacy | 1 | 2019 | 59 | 0.630 |
Why?
|
Antineoplastic Agents | 7 | 2020 | 13630 | 0.630 |
Why?
|
Proton Pump Inhibitors | 1 | 2023 | 534 | 0.600 |
Why?
|
Population Surveillance | 2 | 2018 | 2599 | 0.590 |
Why?
|
Law Enforcement | 1 | 2019 | 112 | 0.580 |
Why?
|
Humans | 146 | 2024 | 761098 | 0.570 |
Why?
|
Abortion, Induced | 1 | 2023 | 462 | 0.560 |
Why?
|
Molecular Targeted Therapy | 5 | 2018 | 2813 | 0.550 |
Why?
|
Antiviral Agents | 2 | 2019 | 3048 | 0.530 |
Why?
|
United States | 42 | 2024 | 72337 | 0.520 |
Why?
|
Metagenomics | 1 | 2019 | 463 | 0.520 |
Why?
|
Liver Diseases | 1 | 2024 | 1300 | 0.500 |
Why?
|
Multifactorial Inheritance | 1 | 2023 | 1381 | 0.490 |
Why?
|
Breast Neoplasms | 14 | 2019 | 20981 | 0.480 |
Why?
|
Leukotriene Antagonists | 1 | 2015 | 124 | 0.470 |
Why?
|
Medically Uninsured | 1 | 2020 | 835 | 0.470 |
Why?
|
Pharmacoepidemiology | 3 | 2018 | 351 | 0.460 |
Why?
|
Databases, Factual | 10 | 2024 | 7969 | 0.460 |
Why?
|
Eye Neoplasms | 1 | 2016 | 307 | 0.460 |
Why?
|
Reproduction | 1 | 2018 | 646 | 0.450 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2018 | 497 | 0.450 |
Why?
|
Ophthalmology | 2 | 2010 | 550 | 0.450 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2014 | 103 | 0.440 |
Why?
|
Liver Cirrhosis | 1 | 2024 | 1932 | 0.440 |
Why?
|
Electronic Health Records | 7 | 2024 | 4813 | 0.440 |
Why?
|
Dengue | 1 | 2016 | 254 | 0.440 |
Why?
|
Clinical Coding | 2 | 2017 | 181 | 0.430 |
Why?
|
Health Care Costs | 6 | 2020 | 3238 | 0.430 |
Why?
|
Evidence-Based Practice | 1 | 2017 | 493 | 0.420 |
Why?
|
Evidence-Based Medicine | 3 | 2015 | 3689 | 0.410 |
Why?
|
Glaucoma | 3 | 2011 | 1186 | 0.400 |
Why?
|
Cost-Benefit Analysis | 9 | 2021 | 5494 | 0.400 |
Why?
|
Insurance, Pharmaceutical Services | 2 | 2012 | 348 | 0.390 |
Why?
|
Hypercholesterolemia | 3 | 2017 | 1141 | 0.390 |
Why?
|
Technology | 1 | 2014 | 294 | 0.390 |
Why?
|
Risk Management | 1 | 2015 | 557 | 0.390 |
Why?
|
Technology Assessment, Biomedical | 1 | 2014 | 306 | 0.390 |
Why?
|
Psychotropic Drugs | 3 | 2024 | 885 | 0.390 |
Why?
|
Delivery of Health Care | 5 | 2023 | 5333 | 0.380 |
Why?
|
Nurses | 1 | 2021 | 2476 | 0.370 |
Why?
|
Erectile Dysfunction | 1 | 2014 | 444 | 0.370 |
Why?
|
Hypolipidemic Agents | 2 | 2017 | 609 | 0.370 |
Why?
|
Antihypertensive Agents | 4 | 2017 | 2019 | 0.360 |
Why?
|
Community Mental Health Centers | 1 | 2011 | 93 | 0.360 |
Why?
|
Middle Aged | 52 | 2024 | 220835 | 0.360 |
Why?
|
Optometry | 1 | 2010 | 29 | 0.360 |
Why?
|
Neoplasms | 9 | 2022 | 22125 | 0.360 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2018 | 1520 | 0.350 |
Why?
|
Asthma | 2 | 2022 | 6229 | 0.350 |
Why?
|
Decision Making | 3 | 2020 | 3925 | 0.350 |
Why?
|
Female | 69 | 2024 | 392458 | 0.340 |
Why?
|
Pyridones | 1 | 2015 | 809 | 0.330 |
Why?
|
Hepatitis C | 1 | 2019 | 1579 | 0.330 |
Why?
|
Hepatitis C, Chronic | 1 | 2017 | 1027 | 0.330 |
Why?
|
Young Adult | 27 | 2024 | 59199 | 0.330 |
Why?
|
Mental Disorders | 9 | 2023 | 6818 | 0.320 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 709 | 0.320 |
Why?
|
Medication Adherence | 2 | 2011 | 2175 | 0.320 |
Why?
|
Ophthalmic Solutions | 1 | 2010 | 312 | 0.320 |
Why?
|
Adult | 48 | 2024 | 221083 | 0.320 |
Why?
|
Depression | 5 | 2024 | 8130 | 0.320 |
Why?
|
Adolescent | 28 | 2024 | 88271 | 0.310 |
Why?
|
Receptor, erbB-2 | 5 | 2018 | 2553 | 0.310 |
Why?
|
Organizational Policy | 1 | 2011 | 432 | 0.310 |
Why?
|
Insurance Coverage | 6 | 2020 | 1937 | 0.300 |
Why?
|
Residence Characteristics | 2 | 2018 | 2092 | 0.300 |
Why?
|
Antirheumatic Agents | 3 | 2007 | 1366 | 0.290 |
Why?
|
Mental Health Services | 3 | 2019 | 1715 | 0.290 |
Why?
|
Aged | 39 | 2024 | 169266 | 0.290 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2024 | 380 | 0.290 |
Why?
|
Tamoxifen | 2 | 2014 | 965 | 0.290 |
Why?
|
Observation | 1 | 2009 | 310 | 0.280 |
Why?
|
Male | 54 | 2024 | 360675 | 0.280 |
Why?
|
Orphan Drug Production | 2 | 2019 | 48 | 0.280 |
Why?
|
Aromatase Inhibitors | 1 | 2011 | 513 | 0.280 |
Why?
|
Thiophenes | 1 | 2011 | 569 | 0.280 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 3245 | 0.270 |
Why?
|
Hypoglycemic Agents | 3 | 2024 | 3086 | 0.270 |
Why?
|
International Classification of Diseases | 3 | 2024 | 913 | 0.260 |
Why?
|
Ambulatory Care | 4 | 2017 | 2769 | 0.250 |
Why?
|
Dementia | 4 | 2024 | 2682 | 0.250 |
Why?
|
Insurance Benefits | 1 | 2007 | 187 | 0.250 |
Why?
|
Risk Assessment | 3 | 2023 | 24013 | 0.250 |
Why?
|
Drug and Narcotic Control | 1 | 2006 | 144 | 0.240 |
Why?
|
Decision Support Techniques | 1 | 2015 | 2000 | 0.240 |
Why?
|
Medication Errors | 1 | 2011 | 783 | 0.240 |
Why?
|
Rheumatic Diseases | 2 | 2009 | 649 | 0.240 |
Why?
|
Suicidal Ideation | 4 | 2024 | 1447 | 0.240 |
Why?
|
Pyrazoles | 1 | 2015 | 2010 | 0.240 |
Why?
|
Insurance Claim Review | 4 | 2020 | 741 | 0.230 |
Why?
|
Epidemiologic Methods | 1 | 2009 | 1336 | 0.230 |
Why?
|
Rheumatoid Factor | 1 | 2004 | 184 | 0.230 |
Why?
|
Medicare | 7 | 2022 | 6775 | 0.220 |
Why?
|
Patient Selection | 3 | 2022 | 4245 | 0.220 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5318 | 0.220 |
Why?
|
Research Design | 5 | 2018 | 6178 | 0.220 |
Why?
|
Receptors, Tumor Necrosis Factor | 1 | 2006 | 585 | 0.220 |
Why?
|
Fees and Charges | 1 | 2004 | 192 | 0.210 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3634 | 0.210 |
Why?
|
Anticonvulsants | 2 | 2011 | 1911 | 0.210 |
Why?
|
Stroke | 2 | 2023 | 9720 | 0.210 |
Why?
|
Risk Factors | 17 | 2024 | 74219 | 0.210 |
Why?
|
Omeprazole | 1 | 2023 | 106 | 0.210 |
Why?
|
Chronic Disease | 3 | 2024 | 9317 | 0.210 |
Why?
|
China | 3 | 2023 | 2374 | 0.210 |
Why?
|
Guideline Adherence | 4 | 2019 | 2218 | 0.200 |
Why?
|
Managed Care Programs | 1 | 2008 | 937 | 0.200 |
Why?
|
Genetic Predisposition to Disease | 2 | 2024 | 17889 | 0.200 |
Why?
|
Diabetes Mellitus, Type 2 | 4 | 2024 | 12145 | 0.200 |
Why?
|
Medical Savings Accounts | 1 | 2022 | 34 | 0.200 |
Why?
|
Policy | 2 | 2023 | 506 | 0.190 |
Why?
|
Case-Control Studies | 15 | 2023 | 22157 | 0.190 |
Why?
|
Health Services | 3 | 2023 | 750 | 0.190 |
Why?
|
Retrospective Studies | 19 | 2024 | 80673 | 0.180 |
Why?
|
Cohort Studies | 15 | 2024 | 41486 | 0.180 |
Why?
|
Aged, 80 and over | 13 | 2024 | 58946 | 0.180 |
Why?
|
Infant, Newborn | 8 | 2024 | 26187 | 0.180 |
Why?
|
Health Services Accessibility | 8 | 2017 | 5427 | 0.180 |
Why?
|
Cause of Death | 2 | 2024 | 3688 | 0.180 |
Why?
|
Piperazines | 1 | 2011 | 2522 | 0.180 |
Why?
|
Adverse Drug Reaction Reporting Systems | 2 | 2018 | 494 | 0.180 |
Why?
|
Comorbidity | 4 | 2014 | 10514 | 0.180 |
Why?
|
Maine | 2 | 2011 | 146 | 0.180 |
Why?
|
Cardiomyopathies | 1 | 2012 | 2021 | 0.180 |
Why?
|
Diabetes Mellitus | 4 | 2022 | 5841 | 0.170 |
Why?
|
Mortality | 2 | 2016 | 2896 | 0.170 |
Why?
|
Substance-Related Disorders | 4 | 2022 | 4414 | 0.170 |
Why?
|
Cost Control | 2 | 2015 | 627 | 0.170 |
Why?
|
Early Detection of Cancer | 4 | 2024 | 3196 | 0.170 |
Why?
|
Family Planning Services | 1 | 2023 | 266 | 0.170 |
Why?
|
Confidentiality | 2 | 2023 | 607 | 0.170 |
Why?
|
Arthritis, Rheumatoid | 2 | 2006 | 3754 | 0.170 |
Why?
|
Early Diagnosis | 1 | 2024 | 1187 | 0.170 |
Why?
|
Communication | 3 | 2022 | 3852 | 0.170 |
Why?
|
Child | 16 | 2024 | 80134 | 0.170 |
Why?
|
Administration, Inhalation | 1 | 2022 | 1157 | 0.170 |
Why?
|
Self Report | 1 | 2011 | 3728 | 0.160 |
Why?
|
Anticoagulants | 1 | 2015 | 4795 | 0.160 |
Why?
|
Cardiovascular Diseases | 4 | 2020 | 15513 | 0.160 |
Why?
|
Simvastatin | 2 | 2023 | 346 | 0.160 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2011 | 2746 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2018 | 3512 | 0.160 |
Why?
|
Longitudinal Studies | 7 | 2018 | 14607 | 0.160 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2019 | 105 | 0.160 |
Why?
|
Drug Approval | 3 | 2019 | 812 | 0.160 |
Why?
|
Costs and Cost Analysis | 3 | 2018 | 1664 | 0.150 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2015 | 10213 | 0.150 |
Why?
|
Anxiety Disorders | 2 | 2019 | 2723 | 0.150 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2021 | 610 | 0.150 |
Why?
|
Pathology, Molecular | 1 | 2021 | 329 | 0.150 |
Why?
|
Biological Products | 1 | 2007 | 913 | 0.150 |
Why?
|
Drugs, Essential | 2 | 2016 | 71 | 0.150 |
Why?
|
Delayed Diagnosis | 2 | 2019 | 465 | 0.150 |
Why?
|
Pregnancy, Multiple | 1 | 2018 | 215 | 0.150 |
Why?
|
Antibodies, Monoclonal | 4 | 2017 | 9185 | 0.150 |
Why?
|
Lung Neoplasms | 2 | 2020 | 13382 | 0.140 |
Why?
|
Horses | 1 | 2018 | 296 | 0.140 |
Why?
|
Ethics, Medical | 1 | 2022 | 786 | 0.140 |
Why?
|
Capital Financing | 1 | 2017 | 58 | 0.140 |
Why?
|
Stomach Ulcer | 1 | 2017 | 122 | 0.140 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2006 | 4340 | 0.140 |
Why?
|
Immunologic Factors | 1 | 2006 | 1589 | 0.130 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 26068 | 0.130 |
Why?
|
Indiana | 3 | 2011 | 92 | 0.130 |
Why?
|
Maytansine | 1 | 2017 | 86 | 0.130 |
Why?
|
Atrial Fibrillation | 1 | 2015 | 5115 | 0.130 |
Why?
|
Veterans | 1 | 2010 | 2652 | 0.130 |
Why?
|
Health Planning | 1 | 2017 | 231 | 0.130 |
Why?
|
Pharmaceutical Preparations | 1 | 2004 | 1086 | 0.130 |
Why?
|
State Medicine | 1 | 2017 | 216 | 0.130 |
Why?
|
Michigan | 3 | 2011 | 339 | 0.130 |
Why?
|
Risk | 3 | 2023 | 9614 | 0.130 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6340 | 0.120 |
Why?
|
Dermatologic Agents | 1 | 2019 | 313 | 0.120 |
Why?
|
Data Collection | 2 | 2019 | 3319 | 0.120 |
Why?
|
Dengue Virus | 1 | 2016 | 201 | 0.120 |
Why?
|
Psychotherapy | 2 | 2016 | 1646 | 0.120 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 686 | 0.120 |
Why?
|
ROC Curve | 1 | 2022 | 3582 | 0.120 |
Why?
|
Penile Erection | 1 | 2014 | 101 | 0.120 |
Why?
|
Economics, Pharmaceutical | 1 | 2015 | 87 | 0.120 |
Why?
|
Geography | 1 | 2016 | 652 | 0.120 |
Why?
|
Health Status Disparities | 2 | 2024 | 1846 | 0.120 |
Why?
|
Forecasting | 2 | 2016 | 2928 | 0.120 |
Why?
|
Health Benefit Plans, Employee | 1 | 2017 | 332 | 0.110 |
Why?
|
Ethylene Glycols | 1 | 2015 | 196 | 0.110 |
Why?
|
Clinical Laboratory Techniques | 2 | 2016 | 746 | 0.110 |
Why?
|
Immunoglobulin G | 1 | 2006 | 4538 | 0.110 |
Why?
|
Decision Support Systems, Clinical | 1 | 2023 | 1171 | 0.110 |
Why?
|
Infant, Low Birth Weight | 1 | 2018 | 869 | 0.110 |
Why?
|
Cardiomyopathy, Hypertrophic | 1 | 2023 | 1312 | 0.110 |
Why?
|
Adrenal Cortex Hormones | 1 | 2022 | 1878 | 0.110 |
Why?
|
Quinazolines | 1 | 2020 | 1371 | 0.110 |
Why?
|
Diabetic Angiopathies | 1 | 2018 | 805 | 0.110 |
Why?
|
Benzodiazepines | 1 | 2019 | 1134 | 0.110 |
Why?
|
Drug Utilization Review | 1 | 2014 | 248 | 0.110 |
Why?
|
Legislation, Drug | 1 | 2015 | 214 | 0.110 |
Why?
|
Vulnerable Populations | 1 | 2019 | 705 | 0.110 |
Why?
|
Algorithms | 1 | 2014 | 14023 | 0.110 |
Why?
|
Gated Blood-Pool Imaging | 1 | 2012 | 44 | 0.110 |
Why?
|
Gatekeeping | 2 | 2010 | 49 | 0.110 |
Why?
|
Socioeconomic Factors | 5 | 2023 | 7804 | 0.100 |
Why?
|
Rural Population | 1 | 2023 | 2277 | 0.100 |
Why?
|
Survivors | 1 | 2023 | 2369 | 0.100 |
Why?
|
Device Approval | 1 | 2014 | 163 | 0.100 |
Why?
|
Drug Therapy, Combination | 1 | 2022 | 6305 | 0.100 |
Why?
|
Medicare Part D | 1 | 2017 | 354 | 0.100 |
Why?
|
Risk-Taking | 1 | 2018 | 1038 | 0.100 |
Why?
|
Time Factors | 8 | 2019 | 39953 | 0.100 |
Why?
|
Off-Label Use | 1 | 2013 | 185 | 0.100 |
Why?
|
Receptors, Cell Surface | 1 | 2021 | 2802 | 0.100 |
Why?
|
Disease | 1 | 2017 | 670 | 0.100 |
Why?
|
Embolism | 1 | 2015 | 399 | 0.100 |
Why?
|
Australasia | 1 | 2011 | 21 | 0.100 |
Why?
|
Child, Preschool | 7 | 2024 | 42217 | 0.090 |
Why?
|
Anthracyclines | 1 | 2013 | 285 | 0.090 |
Why?
|
Research | 1 | 2019 | 1975 | 0.090 |
Why?
|
Hemoglobins | 1 | 2017 | 1525 | 0.090 |
Why?
|
Myocardial Ischemia | 1 | 2021 | 2133 | 0.090 |
Why?
|
Inpatients | 2 | 2019 | 2545 | 0.090 |
Why?
|
Anticholesteremic Agents | 1 | 2017 | 968 | 0.090 |
Why?
|
Firearms | 1 | 2018 | 626 | 0.090 |
Why?
|
Diabetes Complications | 1 | 2017 | 1315 | 0.090 |
Why?
|
Warfarin | 2 | 2016 | 1482 | 0.090 |
Why?
|
New Hampshire | 1 | 2010 | 175 | 0.080 |
Why?
|
Aniline Compounds | 1 | 2015 | 1073 | 0.080 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5662 | 0.080 |
Why?
|
Patient Care Team | 2 | 2011 | 2513 | 0.080 |
Why?
|
Taxoids | 1 | 2013 | 668 | 0.080 |
Why?
|
Cancer Care Facilities | 1 | 2012 | 422 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2024 | 4013 | 0.080 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2017 | 1116 | 0.080 |
Why?
|
Veterans Health | 1 | 2011 | 215 | 0.080 |
Why?
|
Intracranial Hemorrhages | 1 | 2015 | 809 | 0.080 |
Why?
|
Uncertainty | 1 | 2014 | 752 | 0.080 |
Why?
|
Health Care Surveys | 1 | 2016 | 2424 | 0.080 |
Why?
|
Pregnancy | 2 | 2023 | 29872 | 0.080 |
Why?
|
Neoplasm Staging | 3 | 2018 | 11118 | 0.080 |
Why?
|
Infant, Premature | 1 | 2018 | 2106 | 0.080 |
Why?
|
Pharmaceutical Services | 1 | 2010 | 141 | 0.080 |
Why?
|
Hospitalization | 4 | 2018 | 10712 | 0.080 |
Why?
|
Logistic Models | 3 | 2013 | 13254 | 0.080 |
Why?
|
Disease Management | 1 | 2019 | 2508 | 0.080 |
Why?
|
Skin Diseases | 1 | 2017 | 1095 | 0.080 |
Why?
|
Health Care Reform | 1 | 2017 | 1247 | 0.080 |
Why?
|
Models, Organizational | 1 | 2011 | 544 | 0.080 |
Why?
|
Practice Guidelines as Topic | 4 | 2019 | 7400 | 0.080 |
Why?
|
Prevalence | 3 | 2024 | 15717 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2022 | 2577 | 0.070 |
Why?
|
Pregnancy Outcome | 1 | 2018 | 2920 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6482 | 0.070 |
Why?
|
Program Evaluation | 1 | 2016 | 2487 | 0.070 |
Why?
|
North America | 1 | 2011 | 1281 | 0.070 |
Why?
|
Primary Health Care | 3 | 2019 | 4673 | 0.070 |
Why?
|
Mental Health | 2 | 2023 | 3251 | 0.070 |
Why?
|
Disease Outbreaks | 1 | 2016 | 1747 | 0.070 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 2270 | 0.070 |
Why?
|
Allopurinol | 1 | 2008 | 198 | 0.070 |
Why?
|
Health Behavior | 1 | 2018 | 2641 | 0.070 |
Why?
|
Drug Monitoring | 1 | 2012 | 961 | 0.070 |
Why?
|
Depressive Disorder | 1 | 2019 | 3727 | 0.070 |
Why?
|
Premature Birth | 1 | 2018 | 1781 | 0.070 |
Why?
|
Neoplasm Metastasis | 4 | 2017 | 4908 | 0.070 |
Why?
|
Gout Suppressants | 1 | 2008 | 177 | 0.070 |
Why?
|
Data Interpretation, Statistical | 1 | 2016 | 2691 | 0.070 |
Why?
|
Infant | 5 | 2024 | 36164 | 0.060 |
Why?
|
Genetic Variation | 1 | 2021 | 6565 | 0.060 |
Why?
|
Pancreatic Neoplasms | 1 | 2023 | 5366 | 0.060 |
Why?
|
Atherosclerosis | 2 | 2018 | 3405 | 0.060 |
Why?
|
Interprofessional Relations | 1 | 2011 | 989 | 0.060 |
Why?
|
Cost Sharing | 2 | 2020 | 409 | 0.060 |
Why?
|
Radiopharmaceuticals | 1 | 2015 | 2682 | 0.060 |
Why?
|
Heart Failure | 2 | 2023 | 11701 | 0.060 |
Why?
|
Acute Disease | 1 | 2016 | 7240 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2023 | 4575 | 0.060 |
Why?
|
Publication Bias | 1 | 2005 | 160 | 0.060 |
Why?
|
England | 2 | 2017 | 526 | 0.060 |
Why?
|
Thailand | 2 | 2016 | 287 | 0.060 |
Why?
|
Patient Care Planning | 1 | 2010 | 904 | 0.060 |
Why?
|
Health Status Indicators | 1 | 2010 | 970 | 0.060 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2010 | 1242 | 0.060 |
Why?
|
Risk Sharing, Financial | 1 | 2004 | 47 | 0.060 |
Why?
|
Europe | 1 | 2011 | 3422 | 0.060 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 2254 | 0.060 |
Why?
|
Genome-Wide Association Study | 1 | 2023 | 12670 | 0.060 |
Why?
|
Terminology as Topic | 1 | 2011 | 1528 | 0.060 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2019 | 3707 | 0.060 |
Why?
|
Continuity of Patient Care | 1 | 2011 | 1067 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2011 | 940 | 0.050 |
Why?
|
Medical Records | 1 | 2009 | 1409 | 0.050 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12467 | 0.050 |
Why?
|
Community Health Services | 1 | 2008 | 654 | 0.050 |
Why?
|
Pneumonia | 1 | 2014 | 2142 | 0.050 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2015 | 2223 | 0.050 |
Why?
|
Sample Size | 1 | 2005 | 841 | 0.050 |
Why?
|
Pandemics | 1 | 2022 | 8663 | 0.050 |
Why?
|
Drug Industry | 1 | 2009 | 788 | 0.050 |
Why?
|
Hospitals, University | 1 | 2024 | 566 | 0.050 |
Why?
|
Myocardial Infarction | 2 | 2014 | 11475 | 0.050 |
Why?
|
Policy Making | 1 | 2005 | 541 | 0.050 |
Why?
|
Drug Administration Schedule | 1 | 2010 | 4849 | 0.050 |
Why?
|
Financing, Government | 1 | 2005 | 472 | 0.050 |
Why?
|
Patient-Centered Care | 1 | 2011 | 1424 | 0.050 |
Why?
|
Coronary Artery Disease | 1 | 2021 | 6504 | 0.050 |
Why?
|
Pharmacogenetics | 1 | 2005 | 675 | 0.050 |
Why?
|
Gout | 1 | 2008 | 621 | 0.050 |
Why?
|
Healthcare Disparities | 1 | 2016 | 3352 | 0.040 |
Why?
|
Neoplasm Proteins | 1 | 2012 | 3594 | 0.040 |
Why?
|
Schizophrenia | 1 | 2019 | 6929 | 0.040 |
Why?
|
Patient Readmission | 1 | 2014 | 3268 | 0.040 |
Why?
|
Prescriptions | 1 | 2023 | 386 | 0.040 |
Why?
|
Belgium | 1 | 2020 | 118 | 0.040 |
Why?
|
Echocardiography | 1 | 2012 | 5006 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2019 | 5809 | 0.040 |
Why?
|
New South Wales | 2 | 2012 | 69 | 0.040 |
Why?
|
New Zealand | 1 | 2020 | 358 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2011 | 39121 | 0.040 |
Why?
|
Disabled Persons | 1 | 2009 | 1226 | 0.040 |
Why?
|
Hemorrhage | 1 | 2011 | 3422 | 0.040 |
Why?
|
Ribonuclease III | 1 | 2021 | 267 | 0.040 |
Why?
|
Information Storage and Retrieval | 1 | 2024 | 818 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6585 | 0.040 |
Why?
|
Patient Compliance | 1 | 2009 | 2687 | 0.040 |
Why?
|
Muscles | 1 | 2023 | 1567 | 0.040 |
Why?
|
Incidence | 1 | 2016 | 21357 | 0.040 |
Why?
|
DEAD-box RNA Helicases | 1 | 2021 | 380 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2011 | 3603 | 0.040 |
Why?
|
Quality Assurance, Health Care | 1 | 2008 | 2165 | 0.040 |
Why?
|
Physician-Patient Relations | 1 | 2011 | 3238 | 0.040 |
Why?
|
Motivation | 2 | 2019 | 2003 | 0.040 |
Why?
|
Prospective Studies | 2 | 2021 | 54419 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2020 | 335 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 2018 | 6919 | 0.030 |
Why?
|
Mass Screening | 2 | 2024 | 5425 | 0.030 |
Why?
|
Pancreas | 1 | 2023 | 1685 | 0.030 |
Why?
|
Poverty | 2 | 2019 | 2692 | 0.030 |
Why?
|
Biopsy | 2 | 2019 | 6781 | 0.030 |
Why?
|
Retreatment | 1 | 2018 | 598 | 0.030 |
Why?
|
Regression Analysis | 2 | 2016 | 6343 | 0.030 |
Why?
|
Lisinopril | 1 | 2016 | 60 | 0.030 |
Why?
|
Psychotic Disorders | 1 | 2011 | 3219 | 0.030 |
Why?
|
Sentinel Surveillance | 1 | 2017 | 291 | 0.030 |
Why?
|
Syndrome | 1 | 2021 | 3269 | 0.030 |
Why?
|
Survival Analysis | 2 | 2018 | 10083 | 0.030 |
Why?
|
International Normalized Ratio | 1 | 2016 | 382 | 0.030 |
Why?
|
Autistic Disorder | 1 | 2024 | 1222 | 0.030 |
Why?
|
Mood Disorders | 1 | 2020 | 1124 | 0.030 |
Why?
|
Alzheimer Disease | 1 | 2015 | 8601 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2018 | 1702 | 0.030 |
Why?
|
Survival Rate | 2 | 2017 | 12727 | 0.030 |
Why?
|
Marketing | 1 | 2015 | 220 | 0.030 |
Why?
|
France | 1 | 2014 | 492 | 0.030 |
Why?
|
Eligibility Determination | 1 | 2017 | 420 | 0.030 |
Why?
|
Biomedical Research | 1 | 2009 | 3429 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 2017 | 1900 | 0.030 |
Why?
|
Androstadienes | 1 | 2014 | 348 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2009 | 8000 | 0.030 |
Why?
|
Chromosome Mapping | 1 | 2021 | 4612 | 0.030 |
Why?
|
Prescription Drugs | 1 | 2020 | 631 | 0.030 |
Why?
|
Registries | 1 | 2009 | 8236 | 0.030 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2022 | 1187 | 0.030 |
Why?
|
Preventive Health Services | 1 | 2017 | 567 | 0.030 |
Why?
|
Fee-for-Service Plans | 1 | 2017 | 698 | 0.020 |
Why?
|
Refusal to Treat | 1 | 2012 | 44 | 0.020 |
Why?
|
Treatment Outcome | 4 | 2021 | 64670 | 0.020 |
Why?
|
Developed Countries | 1 | 2014 | 448 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4014 | 0.020 |
Why?
|
Outpatients | 1 | 2019 | 1596 | 0.020 |
Why?
|
Incidental Findings | 1 | 2016 | 698 | 0.020 |
Why?
|
Benchmarking | 1 | 2017 | 1045 | 0.020 |
Why?
|
Creatinine | 1 | 2016 | 1897 | 0.020 |
Why?
|
Income | 1 | 2019 | 1868 | 0.020 |
Why?
|
Fees, Pharmaceutical | 1 | 2010 | 66 | 0.020 |
Why?
|
Hypertension | 1 | 2010 | 8537 | 0.020 |
Why?
|
Qualitative Research | 1 | 2020 | 3016 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2016 | 1191 | 0.020 |
Why?
|
Netherlands | 1 | 2014 | 2222 | 0.020 |
Why?
|
Health Services Research | 1 | 2017 | 1807 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2018 | 2181 | 0.020 |
Why?
|
Weight Loss | 1 | 2021 | 2680 | 0.020 |
Why?
|
Nitriles | 1 | 2014 | 971 | 0.020 |
Why?
|
Prostatic Neoplasms | 1 | 2012 | 11103 | 0.020 |
Why?
|
Triazoles | 1 | 2014 | 903 | 0.020 |
Why?
|
Internationality | 1 | 2014 | 1000 | 0.020 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 7873 | 0.020 |
Why?
|
Massachusetts | 1 | 2020 | 8836 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2017 | 6817 | 0.020 |
Why?
|
Mammography | 1 | 2018 | 2430 | 0.020 |
Why?
|
Cardiology | 1 | 2018 | 1693 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4077 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2017 | 2827 | 0.020 |
Why?
|
Animals | 1 | 2018 | 168083 | 0.020 |
Why?
|
Sex Factors | 1 | 2020 | 10552 | 0.020 |
Why?
|
Decision Making, Organizational | 1 | 2005 | 136 | 0.010 |
Why?
|
Pilot Projects | 1 | 2018 | 8639 | 0.010 |
Why?
|
Glucose | 1 | 2016 | 4341 | 0.010 |
Why?
|
Body Mass Index | 1 | 2021 | 12951 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11066 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18385 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15308 | 0.010 |
Why?
|
Advisory Committees | 1 | 2005 | 788 | 0.010 |
Why?
|
Obesity | 1 | 2021 | 12937 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12058 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2009 | 1921 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2015 | 20120 | 0.010 |
Why?
|
Periodicals as Topic | 1 | 2005 | 1463 | 0.010 |
Why?
|
Public Health | 1 | 2005 | 2671 | 0.010 |
Why?
|